Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea

NCT00322907 is registered in ClinicalTrials.gov with Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland as lead sponsor.

NCT NCT00322907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea
Lead sponsor
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2000
Completion date
January 31, 2003
Enrollment
330
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical malaria